IP Library Granted Patent US 9,371,516
Granted Patent B2
US 9,371,516 · App. 14/858,465 · Granted Jun 21, 2016

Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells

Inventors: Xiaofang Xu (Park Ridge, IL); Jon Odorico (Park Ridge, IL); Erik Forsberg (Park Ridge, IL); Amber A. Mael (Madison, WI)
Assignee: REGENERATIVE MEDICAL SOLUTIONS, INC.
C12N5/0676A61K9/1652A61K35/39A61K45/06C12N2501/105C12N2501/115C12N2501/117C12N2501/155C12N2501/16C12N2501/33C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,371,516
App. No.
14/858,465
Granted
Jun 21, 2016
Kind
B2
Abstract

Methods, kits, compositions, and systems are provided for culturing pluripotent stem cells to produce populations of cells comprising beta-like cells (e.g., pancreatic lineage, glucose-responsive, and/or insulin-producing). In particular, culture conditions are provided that result in the generation of beta-like cells from a starting culture of human pluripotent stem cells.

Claims (18)

1. A method of culturing human pluripotent stem cells to produce a cell population comprising pancreatic β-like cells comprising:

(a) culturing the stem cells on an extracellular matrix for 2-4 days in a chemically defined medium, basic fibroblast growth factor, Activin A, and BMP4;

(b) culturing the cells on an extracellular matrix from step (a) for 2-4 days in the presence of chemically defined insulin, transferrin and selenium (ITS) medium, FGF7, and nicotinamide;

(c) culturing the cells on an extracellular matrix from step (b) for 3-5 days in the presence of a chemically defined ITS medium; retinoic acid; Noggin; and nicotinamide; and

(d) culturing the cells on an extracellular matrix from step (c) for 6-10 days in the presence of a B27 serum-free medium, IGF I, IGF II, FGF7, insulin, nicotinamide, exendin-4, an ALK5i II, and forskolin, thereby producing insulin+glucagon−cells that exhibit in vitro glucose stimulated insulin secretion.

2. The method of claim 1 , further comprising:

(e) maintaining the cells from step (d) for 1-14 days by culturing the cells in the presence of B27 serum-free medium, IGF I, FGF7, insulin, nicotinamide, exendin-4, and forskolin.

3. The method of claim 1 , wherein said step (c) is performed in two steps.

4. The method of claim 3 , wherein said first step of step (c) comprises culturing in the presence of chemically defined ITS medium; retinoic acid; and Noggin for 2 days and then culturing in in the presence of chemically defined ITS medium, EGF, and FGF7 for two days.

5. The method of claim 1 , wherein said step (d) further comprises EGF.

6. The method of claim 1 , wherein said step (e) further comprises Warfarin.

7. A method of culturing human pluripotent stem cells to produce a cell population comprising pancreatic β-like cells comprising:

(a) culturing the stem cells on an extracellular matrix for 2-4 days in a chemically defined medium, basic fibroblast growth factor, Activin A, BMP4, LY294002;

(b) culturing the cells from step (a) on an extracellular matrix for 2-4 days in the presence of chemically defined ITS medium, FGF7, nicotinamide;

(c) culturing the cells from step (b) on an extracellular matrix for 2 days in the presence of a chemically defined ITS medium, retinoic acid, Noggin, nicotinamide;

(d) culturing the cells of step (c) for 2 days in the presence of chemically defined insulin, transferrin and selenium (ITS) medium, EGF, and FGF7;

(e) culturing the cells from step (d) on an extracellular matrix for 6-10 days in the presence of a B27 serum-free medium, IGF I, IGF II, FGF7, insulin, Noggin, nicotinamide, exendin-4, ALK5i II, forskolin, thereby producing insulin+glucagon−cells that exhibit in vitro glucose stimulated insulin secretion; and

(f) maintaining the cells of step (e) for 1-50 days by culturing the cells in suspension culture in the presence of a serum-free medium, ALK5, Forskolin, ZnS04, T3, B27, heparin, and antioxidant, Warfarin, and a P13 kinase inhibitor.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2015
From: XU, XIAOFANG; ODORICO, JON; FORSBERG, ERIK; MAEL, AMBER A.
To: REGENERATIVE MEDICAL SOLUTIONS, INC.
Reel/Frame 036950/0875 →
Continuity (3)
Provisional Application 62052894 · Sep 19, 2014
Provisional Application 62173759 · Jun 10, 2015
Related Publication 20160083693A1 · Mar 24, 2016